PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsBupropion
Wellbutrin, Mysimba(bupropion)
Aplenzin, Auvelity, Bupropion, Contrave, Forfivo, Mysimba, Wellbutrin (bupropion) is a small molecule pharmaceutical. Bupropion was first approved as Wellbutrin on 1985-12-30. It is used to treat attention deficit disorder with hyperactivity, depressive disorder, and tobacco use disorder in the USA. It has been approved in Europe to treat obesity and overweight. The pharmaceutical is active against sodium-dependent dopamine transporter and sodium-dependent noradrenaline transporter.
Download report
Favorite
Searched
Top Prescription Drugs
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
signs and symptoms pathological conditionsD013568
chemically-induced disordersD064419
diagnosisD003933
mental disordersD001523
physiological phenomenaD010829
Trade Name
FDA
EMA
Aplenzin, Bupropion, Forfivo, Wellbutrin (discontinued: Bupropion, Wellbutrin, Zyban)
Combinations
Auvelity, Contrave
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bupropion hydrochloride
Tradename
Company
Number
Date
Products
WELLBUTRIN XLBausch Health CompaniesN-021515 RX2003-08-28
2 products, RLD, RS
WELLBUTRIN SRGSKN-020358 RX1996-10-04
3 products, RLD
FORFIVO XLTWi PharmaceuticalsN-022497 RX2011-11-10
1 products, RLD, RS
Show 3 discontinued
Bupropion hydrobromide
Tradename
Company
Number
Date
Products
APLENZINBausch Health CompaniesN-022108 RX2008-04-23
3 products, RLD, RS
Bupropion hydrochloride
+
Dextromethorphan hydrobromide
Tradename
Company
Number
Date
Products
AUVELITYAxsome TherapeuticsN-215430 RX2022-08-18
1 products, RLD, RS
Bupropion hydrochloride
+
Naltrexone hydrochloride
Tradename
Company
Number
Date
Products
CONTRAVENalpropion PharmaceuticalsN-200063 RX2014-09-10
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
aplenzinNew Drug Application2024-03-01
appbutamoneunapproved drug other2011-08-08
appbutamone-dunapproved drug other2011-08-01
auvelityNew Drug Application2024-09-18
budeprionANDA2010-03-25
bupropionANDA2024-10-07
bupropion hclANDA2023-03-30
bupropion hcl erANDA2019-07-25
bupropion hcl er (xl)ANDA2024-05-30
bupropion hcl er bupropion hydrochlorideANDA2019-04-03
Show 16 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
tobacco use disorder—D014029F17
attention deficit disorder with hyperactivityEFO_0003888D001289F90
depressive disorderEFO_1002014D003866F32.A
coughHP_0012735D003371R05
alcoholismEFO_0003829D000437F10.1
opioid-related disordersEFO_0005611D009293F11
drug overdose—D062787—
Agency Specific
FDA
EMA
Expiration
Code
BUPROPION HYDROCHLORIDE / DEXTROMETHORPHAN HYDROBROMIDE, AUVELITY, AXSOME
2025-08-18NP
Patent Expiration
Patent
Expires
Flag
FDA Information
Bupropion Hydrochloride / Dextromethorphan Hydrobromide, Auvelity, Axsome
118447972043-04-20U-3778
118396122043-03-02U-3419
117521442043-02-23U-3419
117307062043-01-23U-3419
118833732043-01-23U-3419
117175182043-01-20U-3419
118965632041-12-01U-3419
107800642040-01-07U-3419
109258422040-01-07U-3419
109401242040-01-07U-3419
109669422040-01-07U-3419
107800662034-11-09U-3419
91682342034-11-05U-3419
91989052034-11-05U-3419
92050832034-11-05U-3419
92380322034-11-05U-3419
92780952034-11-05U-3419
93144622034-11-05U-3419
93705132034-11-05U-3419
93754292034-11-05U-3419
94088152034-11-05U-3419
94211762034-11-05U-3419
94570232034-11-05U-3419
94570252034-11-05U-3419
94747312034-11-05U-3419
94864502034-11-05U-3419
97005282034-11-05U-3419
97005532034-11-05U-3419
97071912034-11-05U-3419
97639322034-11-05U-3419
98615952034-11-05U-3419
98678192034-11-05U-3419
99685682034-11-05U-3419
100585182034-11-05U-3419
100648572034-11-05U-3419
100807272034-11-05U-3419
100925602034-11-05U-3419
100925612034-11-05U-3419
101053272034-11-05U-3419
101053612034-11-05U-3419
102518792034-11-05U-3419
104636342034-11-05U-3419
105126432034-11-05U-3419
105488572034-11-05U-3419
105961672034-11-05U-3419
107728502034-11-05U-3419
107864692034-11-05U-3419
107864962034-11-05U-3419
107994972034-11-05U-3419
108067102034-11-05U-3419
108642092034-11-05U-3419
108746632034-11-05U-3419
108746642034-11-05U-3419
108746652034-11-05U-3419
108816242034-11-05U-3419
108816572034-11-05U-3419
108940462034-11-05U-3419
108940472034-11-05U-3419
108984532034-11-05U-3419
109330342034-11-05U-3419
109459732034-11-05U-3419
109669412034-11-05U-3419
109669742034-11-05U-3419
110203892034-11-05U-3419
110586482034-11-05U-3419
110903002034-11-05U-3419
110969372034-11-05U-3419
111233432034-11-05U-3419
111298262034-11-05U-3419
111413882034-11-05U-3419
111414162034-11-05U-3419
111478082034-11-05U-3419
111855152034-11-05U-3419
111917392034-11-05DPU-3419
111978392034-11-05DPU-3419
112072812034-11-05U-3419
112135212034-11-05U-3419
112296402034-11-05U-3419
112349462034-11-05U-3419
112534912034-11-05U-3419
112534922034-11-05U-3419
112731332034-11-05U-3419
112731342034-11-05U-3419
112851182034-11-05U-3419
112851462034-11-05U-3419
112916382034-11-05U-3419
112916652034-11-05U-3419
112983512034-11-05U-3419
112983522034-11-05U-3419
113115342034-11-05U-3419
113445442034-11-05U-3419
113577442034-11-05U-3419
113642332034-11-05U-3419
113828742034-11-05U-3419
114198672034-11-05U-3419
114263702034-11-05U-3419
114264012034-11-05U-3419
114330672034-11-05DPU-3419
114396362034-11-05U-3419
114784682034-11-05U-3419
114977212034-11-05U-3419
115109182034-11-05U-3419
115175422034-11-05U-3419
115175432034-11-05U-3419
115240072034-11-05U-3419
115240082034-11-05U-3419
115344142034-11-05DPU-3419
115410212034-11-05U-3419
115410482034-11-05U-3419
115966272034-11-05U-3419
116177282034-11-05U-3419
116177472034-11-05U-3563
117795792034-11-05U-3419
85693282033-10-29DPU-3419
Bupropion Hydrochloride / Naltrexone Hydrochloride, Contrave, Nalpropion
102319642034-07-02U-1583
108282942034-07-02U-1583
108355272034-07-02U-1583
96335752033-06-25U-1583
104031702033-06-05U-1583
111390562033-06-05U-1583
92481232032-01-13U-1808
110335432031-01-10U-1583
89161952030-02-02U-1639
113247412029-05-29U-1583
80887862029-02-03DP
83187882027-11-08U-1584
87220852027-11-08U-1585
91258682027-11-08U-1585
103073762027-11-08U-1585
91078372027-06-04U-1639
73751112025-03-26DP
74626262024-07-20U-1583
88158892024-07-20U-1586
112785442024-04-21U-1583
Bupropion Hydrochloride, Forfivo Xl, Twi Pharms
76744792027-06-25DP
Bupropion Hydrobromide, Aplenzin, Bausch
72418052026-06-27DP
75696102026-06-27U-997
75729352026-06-27DP
75858972026-06-27DP
76458022026-06-27DP
76490192026-06-27DP
76624072026-06-27DP
76710942026-06-27DP
ATC Codes
A: Alimentary tract and metabolism drugs
— A08: Antiobesity preparations, excl. diet products
— A08A: Antiobesity preparations, excl. diet products
— A08AA: Centrally acting antiobesity products
— A08AA62: Bupropion and naltrexone
N: Nervous system drugs
— N06: Psychoanaleptics
— N06A: Antidepressants
— N06AX: Other antidepressants in atc
— N06AX12: Bupropion
HCPCS
Code
Description
S0106
Bupropion hcl sustained release tablet, 150 mg, per bottle of 60 tablets
Clinical
Clinical Trials
463 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Depressive disorderD003866EFO_1002014F32.A1018204018104
DepressionD003863—F33.961618411695
Major depressive disorderD003865EFO_0003761F2251217321075
Tobacco use disorderD014029—F1762214241474
Smoking cessationD016540EFO_0004319—1914152361
ObesityD009765EFO_0001073E66.91141514541
Healthy volunteers/patients———27——2332
SmokingD012907EFO_0004318—35591231
SchizophreniaD012559EFO_0000692F201619118
OverweightD050177—E66.31791217
Show 80 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C803—1—59
BulimiaD002032—F50.2—66—17
Feeding and eating disordersD001068—F50—66—17
Binge-eating disorderD056912—F50.2—66—17
Cocaine-related disordersD019970—F14233—17
Alzheimer diseaseD000544EFO_0000249F03115——6
Psychomotor agitationD011595———25——5
SyndromeD013577——122—14
Non-small-cell lung carcinomaD002289——111—13
Acute coronary syndromeD054058EFO_0005672—111—13
Show 15 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Kidney diseasesD007674EFO_0003086N0812——13
CarcinomaD002277—C80.011——13
Marijuana abuseD002189EFO_0007191F12—2——13
PregnancyD011247EFO_0002950Z33.1—1——23
Amphetamine-related disordersD019969EFO_0004701F1512———3
Ovarian neoplasmsD010051EFO_0003893C5611———2
Insulin resistanceD007333HP_0000855——1——12
Chronic renal insufficiencyD051436—N18—1——12
StrokeD020521EFO_0000712I63.9—1——12
Coronary artery diseaseD003324—I25.1—1——12
Show 17 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Drug interactionsD004347——3———14
Drug-related side effects and adverse reactionsD064420—T88.71———12
Squamous cell carcinoma of head and neckD000077195——1———12
Squamous cell carcinomaD002294——1———12
TuberculosisD014376EFO_0000774A15-A191———12
Pulmonary tuberculosisD014397EFO_1000049A151———12
MetabolismD008660GO_0008152—1———12
MelanomaD008545——1————1
Mitochondrial diseasesD028361EFO_0000591—1————1
Ovarian epithelial carcinomaD000077216——1————1
Show 12 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PeriodontitisD010518EFO_0000649K05.3————22
Congenital abnormalitiesD000013EFO_0003915Q89.9————22
LactationD007774——————11
Health behaviorD015438——————11
AggressionD000374EFO_0003015—————11
Palliative careD010166——————11
Coronary diseaseD003327——————11
Myocardial ischemiaD017202EFO_1001375I20-I25————11
Vitamin d deficiencyD014808EFO_0003762E55————11
AvitaminosisD001361EFO_0005878E56.9————11
Show 16 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBupropion
INNbupropion
Description
Bupropion is an aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring. It has a role as an antidepressant, an environmental contaminant and a xenobiotic. It is a secondary amino compound, a member of monochlorobenzenes and an aromatic ketone.
Classification
Small molecule
Drug classNDRI antidepressants
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
Identifiers
PDB—
CAS-ID34841-39-9
RxCUI—
ChEMBL IDCHEMBL894
ChEBI ID3219
PubChem CID444
DrugBankDB01156
UNII ID01ZG3TPX31 (ChemIDplus, GSRS)
Target
Agency Approved
SLC6A3
SLC6A3
SLC6A2
SLC6A2
Organism
Homo sapiens
Gene name
SLC6A3
Gene synonyms
DAT1
NCBI Gene ID
6531
Protein name
sodium-dependent dopamine transporter
Protein synonyms
DA transporter, dopamine transporter 1, solute carrier family 6 (neurotransmitter transporter), member 3, solute carrier family 6 (neurotransmitter transporter, dopamine), member 3, Solute carrier family 6 member 3
Uniprot ID
Q14996
Mouse ortholog
Slc6a3 (13162)
sodium-dependent dopamine transporter (Q9R1I2)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Bupropion
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 18,891 documents
View more details
Safety
Black-box Warning
Black-box warning for: Aplenzin, Appbutamone, Appbutamone-d, Auvelity, Budeprion, Bupropion, Bupropion hcl, Bupropion hcl er, Bupropion hcl er (xl), Bupropion hcl er bupropion hydrochloride, Bupropion hydrochloride, Bupropion hydrochloride bupropion hydrochloride, Bupropion hydrochloride (sr), Bupropion hydrochloride (xl), Bupropion hydrochloride bupropion hydrochloride, Bupropion hydrochloride extended release, Bupropion hydrochloride extended-release, Bupropion hydrochloride sr, Bupropion hydrochloridexl, Bupropionhydrochloridetablets, Contrave, Forfivo, Wellbutrin, Wellbutrin sr, Wellbutrin xl
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
44,578 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use